The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 327-338

  Agnew, Andrew J ^a   Robinson, Emma ^a   McVicar, Carmel M ^a   Harvey, Adam P ^a   Ali, Imran H A ^a   Lindsay, Jennifer E ^a   McDonald, Denise M ^a   Green, Brian D ^a   Grieve, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

aorta; diabetes; endothelium; mesenteric artery; nitric oxide; obestatin; vasorelaxation

Indexed keywords

CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; OBESTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ISOLATED ARTERY; MALE; MESENTERIC ARTERY; NONHUMAN; POTASSIUM CELL LEVEL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA; CALCIUM; CATTLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; PEPTIDE HORMONES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84859722696     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01761.x     Document Type: Article

References (63)

1. Agnew A, Calderwood D, Chevallier OP, Greer B, Grieve DJ, Green BD, (2011). Chronic treatment with a stable obestatin analogue significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats. Peptides 32: 755-762.
2. Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghe C, et al,. (2010). Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 299: H470-H481.
3. Anderwald-Stadler M, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P, et al,. (2007). Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans. Am J Physiol Endocrinol Metab 293: E1393-E1398.
4. 2+/calmodulin-dependent protein kinase II. Invest Ophthalmol Vis Sci 52: 3103-3111.
5. Bassil AK, Haglund Y, Brown J, Rudholm T, Hellstrom PM, Naslund E, et al,. (2007). Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. Br J Pharmacol 150: 58-64.
6. Beck B, Bossenmeyer-Pourie C, Pourie G, (2010). Association of neuropeptide W, but not obestatin, with energy intake and endocrine status in Zucker rats. A new player in long-term stress-feeding interactions. Appetite 55: 319-324.
7. Bolego C, Pinna C, Abbracchio MP, Cattabeni F, Puglisi L, (1995). The biphasic response of rat vesical smooth muscle to ATP. Br J Pharmacol 114: 1557-1562.
8. Booyse FM, Sedlak BJ, Rafelson ME Jr, (1975). Culture of arterial endothelial cells: characterization and growth of bovine aortic cells. Thromb Diath Haemorrh 34: 825-839.
9. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH, (2002). EDHF: bringing the concepts together. Trends Pharmacol Sci 23: 374-380.
10. Camina JP, Campos JF, Caminos JE, Dieguez C, Casanueva FF, (2007). Obestatin-mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. J Cell Physiol 211: 1-9.
11. Carlini VP, Schioth HB, Debarioglio SR, (2007). Obestatin improves memory performance and causes anxiolytic effects in rats. Biochem Biophys Res Commun 352: 907-912.
12. Chartrel N, Alvear-Perez R, Leprince J, Iturrioz X, Reaux-Le Goazigo A, Audinot V, et al,. (2007). Comment on 'Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 315: 766.
13. Davies SP, Reddy H, Caivano M, Cohen P, (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
14. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
15. Feletou M, Vanhoutte PM, (2009). EDHF: an update. Clin Sci (Lond) 117: 139-155.
16. Furnes MW, Stenstrom B, Tommeras K, Skoglund T, Dickson SL, Kulseng B, et al,. (2008). Feeding behavior in rats subjected to gastrectomy or gastric bypass surgery. Eur Surg Res 40: 279-288.
17. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, et al,. (1990). Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 265: 11083-11090.
18. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B, (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
19. Gourcerol G, Tache Y, (2007). Obestatin-a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil 19: 161-165.
20. Grala TM, Kay JK, Walker CG, Sheahan AJ, Littlejohn MD, Lucy MC, et al,. (2010). Expression analysis of key somatotropic axis and liporegulatory genes in ghrelin- and obestatin-infused dairy cows. Domest Anim Endocrinol 39: 76-83.
21. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al,. (2008). Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 57: 967-979.
22. Granata R, Volante M, Settanni F, Gauna C, Ghe C, Annunziata M, et al,. (2010). Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol 45: 9-17.
23. Green BD, Irwin N, Flatt PR, (2007). Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 28: 981-987.
24. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ, (2008). GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478: 136-142.
25. Grieve DJ, Avella MA, Botham KM, Elliott J, (1998). Effects of chylomicrons and chylomicron remnants on endothelium-dependent relaxation of rat aorta. Eur J Pharmacol 348: 181-190.
26. Grieve DJ, Cassidy RS, Green BD, (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
27. Gurriaran-Rodriguez U, Al-Massadi O, Roca-Rivada A, Crujeiras AB, Gallego R, Pardo M, et al,. (2010). Obestatin as a regulator of adipocyte metabolism and adipogenesis. J Cell Mol Med 15: 1927-1940.
28. Hamilton SJ, Chew GT, Watts GF, (2007). Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 4: 89-102.
29. Hammarstrom S, (1977). Selective inhibition of platelet n-8 lipoxygenase by 5,8,11-eicosatriynoic acid. Biochim Biophys Acta 487: 517-519.
30. Henning RJ, Sawmiller DR, (2001). Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49: 27-37.
31. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, et al,. (2007). GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148: 13-20.
32. Hunt NH, Evans T, (1980). RMI 12330A, an inhibitor of cyclic nucleotide phosphodiesterases and adenylate cyclase in kidney preparations. Biochim Biophys Acta 613: 499-506.
33. Kellokoski E, Kunnari A, Jokela M, Makela S, Kesaniemi YA, Horkko S, (2009). Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 58: 1572-1580.
34. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W, (2006). Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 351: 21-25.
35. Li ZF, Song SW, Qin YW, Zhang JL, Zhao XX, Zhang BL, et al,. (2009). Bolus intravenous injection of obestatin does not change blood pressure level of spontaneously hypertensive rat. Peptides 30: 1928-1930.
36. Li ZF, Guo ZF, Cao J, Hu JQ, Zhao XX, Xu RL, et al,. (2010a). Plasma ghrelin and obestatin levels are increased in spontaneously hypertensive rats. Peptides 31: 297-300.
37. Li ZF, Guo ZF, Yang SG, Zheng X, Cao J, Qin YW, (2010b). Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul Pept 165: 206-209.
38. Lincoln TM, Dey N, Sellak H, (2001). Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91: 1421-1430.
39. Lippl F, Erdmann J, Lichter N, Tholl S, Wagenpfeil S, Adam O, et al,. (2008). Relation of plasma obestatin levels to bmi, gender, age and insulin. Horm Metab Res 40: 806-812.
40. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, et al,. (2008). Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51: 319-325.
41. Marchenko SM, Sage SO, (1996). Calcium-activated potassium channels in the endothelium of intact rat aorta. J Physiol 492: 53-60.
42. Mian KB, Martin W, (1995). The inhibitory effect of 3-amino-1,2,4- triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta. Br J Pharmacol 116: 3302-3308.
43. Moncada S, Palmer RM, Higgs EA, (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
44. Nagaraj S, Peddha MS, Manjappara UV, (2008). Fragments of obestatin as modulators of feed intake, circulating lipids, and stored fat. Biochem Biophys Res Commun 366: 731-737.
45. Pan W, Tu H, Kastin AJ, (2006). Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 27: 911-916.
46. Pazos Y, Alvarez CJ, Camina JP, Al-Massadi O, Seoane LM, Casanueva FF, (2009). Role of obestatin on growth hormone secretion: an in vitro approach. Biochem Biophys Res Commun 390: 1377-1381.
47. Qi X, Li L, Yang G, Liu J, Li K, Tang Y, et al,. (2007). Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66: 593-597.
48. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S, (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752.
49. Samson WK, White MM, Price C, Ferguson AV, (2007). Obestatin acts in brain to inhibit thirst. Am J Physiol Regul Integr Comp Physiol 292: R637-R643.
50. Sanchez-Fernandez C, Gonzalez MC, Beart PM, Mercer LD, Ruiz-Gayo M, Fernandez-Alfonso MS, (2004). A novel role for cholecystokinin: regulation of mesenteric vascular resistance. Regul Pept 121: 145-153.
51. Sazdova IV, Ilieva BM, Minkov IB, Schubert R, Gagov HS, (2009). Obestatin as contractile mediator of excised frog heart. Cent Eur J Biol 4: 327-334.
52. 2+/calmodulin- dependent protein kinase II in endothelial NO production and endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol 284: H2311-H2319.
53. Scrima M, Campiglia P, Esposito C, Gomez-Monterrey I, Novellino E, D'Ursi AM, (2007). Obestatin conformational features: a strategy to unveil obestatin's biological role? Biochem Biophys Res Commun 363: 500-505.
54. St-Pierre DH, Settanni F, Olivetti I, Gramaglia E, Tomelini M, Granata R, et al,. (2010). Circulating obestatin levels in normal and Type 2 diabetic subjects. J Endocrinol Invest 33: 211-214.
55. Subasinghage AP, Green BD, Flatt PR, Irwin N, Hewage CM, (2010). Metabolic and structural properties of human obestatin {1-23} and two fragment peptides. Peptides 31: 1697-1705.
56. Szentirmai E, Krueger JM, (2006). Obestatin alters sleep in rats. Neurosci Lett 404: 222-226.
57. Unniappan S, Speck M, Kieffer TJ, (2008). Metabolic effects of chronic obestatin infusion in rats. Peptides 29: 1354-1361.
58. Vane JR, (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232-235.
59. Wang JY, Wang LH, Wei LZ, Wu J, Wei N, Kong XJ, et al,. (2010). Association of gastric emptying with ghrelin, obestatin and receptor (GHSR, GPR-39) in hypothalamus of diabetic rats. Zhonghua Yi Xue Za Zhi 90: 1137-1140.
60. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, et al,. (1998). Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966-973.
61. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG, (2000). Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97: 8151-8156.
62. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al,. (2005). Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310: 996-999.
63. Zhao CM, Furnes MW, Stenstrom B, Kulseng B, Chen D, (2008). Characterization of obestatin- and ghrelin-producing cells in the gastrointestinal tract and pancreas of rats: an immunohistochemical and electron-microscopic study. Cell Tissue Res 331: 575-587.